Thông tin thuốc gốc
Chỉ định và Liều dùng
Acute treatment of nausea and vomiting
Adult: 10 mg up to 3 times daily. Max: 30 mg daily. Max treatment duration: 7 days. Use the lowest effective dose for the shortest possible duration.
Child: <12 years <35 kg: 0.25 mg/kg given up to 3 times daily. Max: 0.75 mg/kg daily. ≥12 years ≥35 kg: Same as adult dose.

Nausea and vomiting
Adult: 30 mg bid. Max treatment duration: 7 days.
Child: <12 years <35 kg: 0.75 mg/kg bid. ≥12 years ≥35 kg: Same as adult dose.
Suy thận
Severe: Reduce dose and dosing frequency to 1 or 2 times daily depending on the severity of the impairment for repeated administration.
Suy gan
Moderate to severe: Contraindicated.
Cách dùng
Should be taken on an empty stomach. Take 15-30 min before meals.
Chống chỉ định
Prolactin-releasing pituitary tumour (prolactinoma), existing QTc interval prolongation, significant electrolyte disturbances (e.g. hypokalaemia, hypomagnesaemia, hyperkalaemia), underlying cardiac disease (e.g. CHF), gastrointestinal haemorrhage, mechanical obstruction or perforation. Moderate to severe hepatic impairment. Concomitant use with QT-prolonging drugs, and potent CYP3A4 inhibitors e.g. ketoconazole, macrolide (e.g. erythromycin), protease inhibitors, or nefazodone.
Thận trọng
Patients with personal or family history of breast cancer, risk factors for sudden cardiac death (e.g. family history of coronary artery disease, high blood pressure, high blood cholesterol, diabetes mellitus, obesity, smoking, excessive alcohol consumption). Renal and mild hepatic impairment. Children and elderly. Pregnancy and lactation.
Phản ứng phụ
Significant: Elevated prolactin levels, hypersensitivity reactions (e.g. anaphylaxis, angioedema). Rarely, neurological or extrapyramidal side effects (in children).
Eye disorders: Oculogyric crisis.
Gastrointestinal disorders: Dry mouth, diarrhoea, transient intestinal cramps.
General disorders and admin site conditions: Asthenia.
Immune system disorders: Urticaria.
Investigations: Abnormal LFT.
Nervous system disorders: Headache, migraine, dizziness, convulsions.
Psychiatric disorders: Anxiety, agitation, nervousness, loss of libido, somnolence.
Renal and urinary disorders: Urinary retention.
Reproductive system and breast disorders: Galactorrhoea, breast pain or tenderness, gynaecomastia, amenorrhoea.
Skin and subcutaneous tissue disorders: Rash, pruritus.
Potentially Fatal: Serious ventricular arrhythmias, sudden cardiac death, QT interval prolongation, torsades de pointes.
Thông tin tư vấn bệnh nhân
This drug may cause dizziness and somnolence, if affected, do not drive or operate machinery.
Chỉ số theo dõi
Monitor ECG, renal function at baseline and periodically during treatment.
Quá liều
Symptoms: Agitation, altered consciousness, somnolence, disorientation, convulsions, and extrapyramidal reactions. Management: Symptomatic and supportive treatment. May perform gastric lavage and administer activated charcoal. Consider anticholinergic or anti-Parkinsonian drugs to control extrapyramidal reactions. Monitor ECG for possible QT interval prolongation.
Tương tác
May increase risk of QT interval prolongation with azithromycin, roxithromycin, and with bradycardia- and hypokalaemia-inducing drugs. May decrease bioavailability with antacids or antisecretory agents. May antagonise the prokinetic effects of anticholinergics (e.g. bromocriptine). Increased plasma concentrations of levodopa.
Potentially Fatal: Increased risk of QT interval prolongation with potent CYP3A4 inhibitors (e.g. protease inhibitors, systemic azole antifungals, clarithromycin, telithromycin, nefazodone), moderate CYP3A4 inhibitors (e.g. diltiazem, verapamil), and QT-prolonging drugs (e.g. quinidine, disopyramide, dofetilide, amiodarone, haloperidol, pimozide, citalopram, erythromycin, levofloxacin, pentamidine, halofantrine, lumefantrine, cisapride, dolasetron, mizolastine, mequitazine, toremifene, vandetanib, vincamine, bepridil, methadone; apomorphine [unless the benefit outweighs the risk and recommended precaution is strictly fulfilled]).
Tương tác với thức ăn
May increase serum concentration with grapefruit or grapefruit juice. Slightly delayed absorption with food.
Tác dụng
Description: Domperidone is a peripheral dopamine-receptor blocker. It increases oesophageal peristalsis, lower oesophageal sphincter pressure, gastric motility and peristalsis, and enhances gastroduodenal coordination, thereby facilitating gastric emptying and decreasing small bowel transit time.
Absorption: Rapidly absorbed from the gastrointestinal tract. Slightly delayed absorption with food. Bioavailability: Approx 15%. Time to peak plasma concentration: Approx 30 minutes.
Distribution: Does not readily cross the blood-brain barrier. Enters breast milk (small amounts). Plasma protein binding: Approx 93%.
Metabolism: Rapidly and extensively metabolised in the liver via N-dealkylation by CYP3A4 isoenzyme and via hydroxylation by CYP3A4, CYP1A2 and CYP2E1 isoenzymes.
Excretion: Mainly via faeces (66%, 10% as unchanged drug); urine (31%; mainly as metabolites, approx 1% as unchanged drug). Elimination half-life: Approx 7.5 hours.
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Domperidone, CID=3151, (accessed on Jan. 21, 2020)

Bảo quản
Store between 15-30°C. Protect from light and moisture.
Phân loại MIMS
Thuốc chống nôn / Thuốc điều hòa tiêu hóa, chống đầy hơi & kháng viêm
Phân loại ATC
A03FA03 - domperidone ; Belongs to the class of propulsives. Used in the treatment of functional gastrointestinal disorders.
Tài liệu tham khảo
Anon. Domperidone. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 19/09/2019.

Buckingham R (ed). Domperidone. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 19/09/2019.

Janssen-Cilag (New Zealand) Ltd. Motilium 10 mg Film-Coated Tablets data sheet 01 June 2018. Medsafe. Accessed 19/09/2019.

Joint Formulary Committee. Domperidone. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 19/09/2019.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Domperidone từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
  • Agimoti
  • Apo-Domperidone
  • Apuldon
  • Bivior
  • Cadiperidon
  • Cadiramid
  • Cinet
  • Crown Domperidone
  • Curedom
  • Darida
  • Domfeboston
  • Domilume
  • Domne
  • Dompenyl-M
  • Domperidon Uphace
  • Domperidon-BVP
  • Domperidone Daewon
  • Domperidone GSK
  • Domperidone TV Pharm
  • Domperon
  • Dompidone
  • Dompil
  • Domreme
  • Domridon
  • Domridon-M
  • Domsimix
  • Domstal/Torolium MT
  • Donalium
  • Dotium
  • Eftirlium
  • Esogut Drop
  • Esogut Suspension
  • KMS Domperidone Maleate
  • Maxidom
  • Modom-S
  • Modon-M
  • Mofirum
  • Motidom
  • Motilium Hỗn dịch
  • Motinorm tabs/drops
  • Newgene Domperidone
  • Ompel-M
  • Operidone
  • Oriner
  • Pedomcad
  • Pedomcad suspension
  • Peridom-M
  • Potaridone
  • Pyme Pelium
  • Ragozax
  • Regurgex
  • Sagolium-M
  • Savidome
  • Shidom
  • Soltina
  • SP-Dom
  • Unidone-M
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in